# Karl D. Lewis

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/karl-d-lewis/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,338 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 61 |
| i10-index | 144 |
| Last Known Institution | Regeneron (United States) |
| OpenAlex ID | https://openalex.org/A5010628808 |
| ORCID iD | https://orcid.org/0000-0001-9893-0537 |
| Works | 350 |

## Researcher papers

- [Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma](https://scholariq.org/papers/efficacy-and-safety-of-vismodegib-in-advanced-basal-cell-carcinoma/)
- [Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial](https://scholariq.org/papers/activity-of-the-oral-mek-inhibitor-trametinib-in-patients-with-advanced-melanoma/)
- [Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor](https://scholariq.org/papers/phase-ii-study-of-the-mek1-mek2-inhibitor-trametinib-in-patients-with-metastatic/)
- [Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial](https://scholariq.org/papers/treatment-with-two-different-doses-of-sonidegib-in-patients-with-locally/)
- [Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study](https://scholariq.org/papers/efficacy-and-safety-of-lifileucel-a-one-time-autologous-tumor-infiltrating/)
- [Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/merkel-cell-carcinoma-version-1-2018-nccn-clinical-practice-guidelines-in/)
- [Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial](https://scholariq.org/papers/cemiplimab-in-locally-advanced-basal-cell-carcinoma-after-hedgehog-inhibitor/)
- [Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study](https://scholariq.org/papers/long-term-efficacy-and-safety-of-sonidegib-in-patients-with-advanced-basal-cell/)
- [Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study](https://scholariq.org/papers/long-term-efficacy-and-safety-of-sonidegib-in-patients-with-locally-advanced-and/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Regeneron (United States)](https://scholariq.org/institutions/regeneron-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.